Positive Clinical Results for Using Myriad's BRACAnalysis...

Positive Clinical Results for Using Myriad's BRACAnalysis...


Myriad Genetics recently announced clinical results showing that its BRACAnalysis CDx test was able to identify patients with HER2-negative metastatic breast cancer who had improved response with Lynparza , AstraZeneca's PARP inhibitor. The results are based on a collaborative effort between Myriad Genetics and AstraZeneca for identification and treatment of patients with metastatic breast cancer and underlying BRCA 1/2 mutations.



from Biotech News